株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病の世界市場分析:タイプ(血友病A、血友病B、血友病C)、処置(オンデマンド補充療法、定期的補充療法)、治療法別(補充療法、遺伝子治療)別 2019年~2026年

Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 368045
出版日 ページ情報 英文 119 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
血友病の世界市場分析:タイプ(血友病A、血友病B、血友病C)、処置(オンデマンド補充療法、定期的補充療法)、治療法別(補充療法、遺伝子治療)別 2019年~2026年 Hemophilia Market Analysis by Type (Hemophilia A, Hemophilia B, Hemophilia C), by Treatment (On-demand, Prophylaxis), by Therapy (Replacement Therapy, Gene Therapy), And Segment Forecasts, 2019 - 2026
出版日: 2019年02月25日 ページ情報: 英文 119 Pages
概要

世界の血友病市場は、2026年までに169億米ドル規模の市場に成長すると予測されています。予防的治療を実施するために行われる対象集団の診断の必要性の高まりや、政府の血友病支援プログラムなどが当市場の成長を促進しています。

当レポートでは、世界の血友病市場を調査し、市場の概要、タイプ・処置・治療法・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場シェア、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法と範囲

  • 市場区分と範囲
  • 情報調達
  • 情報分析
  • 市場構成とデータの可視化
  • データ検証と公開

第2章 エグゼクティブサマリー

  • 市場の見通し
  • 市場の見通し:セグメント別
  • 競争洞察

第3章 市場変数・傾向・範囲

  • 市場の見通し
  • 浸透および成長の見通し
  • パイプライン分析:治験段階別
  • 利用者観点の分析
  • 主要エンドユーザー:製品・地域/国別
  • 規制の枠組み
  • 市場力学
  • 市場分析ツール

第4章 世界の血友病市場の分析:タイプ別

  • 定義と範囲
  • 市場シェアの分析:タイプ別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:タイプ別
  • 市場規模の推移と予測:タイプ別
    • 血友病 A
    • 血友病 B
    • 血友病 C
    • その他

第5章 世界の血友病市場の分析:治療法別

  • 定義と範囲
  • 市場シェアの分析:治療法別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:治療法別
  • 市場規模の推移と予測:治療法別
    • 補充療法
    • 免疫寛容導入療法
    • 遺伝子療法

第6章 世界の血友病市場の分析:処置別

  • 定義と範囲
  • 市場シェアの分析:処置別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:処置別
  • 市場規模の推移と予測:処置別
    • オンデマンド補充療法(出血時補充療法)
    • 定期的補充療法

第7章 世界の血友病市場の分析:地域別

  • 定義と範囲
  • 市場シェアの分析:地域別(実績値・予測値)
  • セグメントダッシュボード
  • 市場スナップショット
  • 市場シェア & 主要企業:地域別
  • SWOT分析:地域別
  • 市場規模の推移と予測:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 競合分析

  • 主要参入企業の近年の動向と影響分析
  • 企業区分(イノベーター・マーケットリーダー・新興企業)
  • ベンダー情勢
  • 公開会社
  • 民間企業
  • サプライヤーランキング
  • 主要企業のプロファイル
    • Novo Nordisk
    • Biogen.
    • 中外製薬
    • Bayer Healthcare
    • Pfizer.
    • Shire Plc
    • Baxalta (Baxter Healthcare)
    • CSL Behring.
    • Octapharma

第9章 キーオピニオンリーダーの解説

第10章 提言

図表

List of Tables

  • TABLE 1 Hemophilia market - Key market driver analysis
  • TABLE 2 Co-pay programs for hemophilia treatment
  • TABLE 3 Product pipeline for hemophilia drugs, 2015
  • TABLE 4 Hemophilia - Key market restraint analysis
  • TABLE 5 North America hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 6 North America hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 7 North America hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 8 U.S. hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 9 U.S. hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 10 U.S. hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 11 Canada hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 12 Canada hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 13 Canada hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 14 Europe hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 15 Europe hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 16 Europe hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 17 UK hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 18 UK hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 19 UK hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 20 Germany hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 21 Germany hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 22 Germany hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 23 France hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 24 France hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 25 France hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 26 Spain hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 27 Spain hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 28 Spain hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 29 Italy hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 30 Italy hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 31 Italy hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 32 Asia Pacific hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 33 Asia Pacific hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 34 Asia Pacific hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 35 Japan hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 36 Japan hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 37 Japan hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 38 China hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 39 China hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 40 China hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 41 India hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 42 India hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 43 India hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 44 South Korea hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 45 South Korea hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 46 South Korea hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 47 Thailand hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 58 Thailand hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 59 Thailand hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 60 Latin America hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 61 Latin America hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 62 Latin America hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 63 Brazil hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 64 Brazil hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 65 Brazil hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 66 Mexico hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 67 Mexico hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 68 Mexico hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 69 Argentina hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 70 Argentina hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 71 Argentina hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 72 Columbia hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 73 Columbia hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 74 Columbia hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 75 MEA hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 76 MEA hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 77 MEA hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 78 MEA hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 79 South Africa hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 80 South Africa hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 81 South Africa hemophilia market, by therapy, 2015 - 2026 (USD Million)
  • TABLE 82 Saudi Arabia hemophilia market, by type, 2015 - 2026 (USD Million)
  • TABLE 83 Saudi Arabia hemophilia market, by treatment, 2015 - 2026 (USD Million)
  • TABLE 84 Saudi Arabia hemophilia market, by therapy, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modeling for market share assessment
  • FIG. 7 Market summary (Figures in USD Million, 2015)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Hemophilia market: Market Segmentation
  • FIG. 10 Hemophilia market revenue, 2015 - 2026 (USD Million)
  • FIG. 11 Key Opportunities Prioritized
  • FIG. 12 Hemophilia Porter's analysis
  • FIG. 13 Hemophilia PESTEL analysis
  • FIG. 14 Hemophilia market type outlook key takeaways
  • FIG. 15 Hemophilia market: Type movement analysis
  • FIG. 16 Hemophilia A market, 2015 - 2026 (USD Million)
  • FIG. 17 Hemophilia B market, 2015 - 2026 (USD Million)
  • FIG. 18 Hemophilia C market, 2015 - 2026 (USD Million)
  • FIG. 19 Others market, 2015 - 2026 (USD Million)
  • FIG. 20 Hemophilia market treatment outlook key takeaways
  • FIG. 21 Hemophilia market: Treatment movement analysis
  • FIG. 22 On-demand treatment market, 2015 - 2026 (USD Million)
  • FIG. 23 Prophylaxis treatment market, 2015 - 2026 (USD Million)
  • FIG. 24 Hemophilia market therapy outlook key takeaways
  • FIG. 25 Hemophilia market: Therapy movement analysis
  • FIG. 26 Replacement therapy market, 2015 - 2026 (USD Million)
  • FIG. 27 ITI therapy market, 2015 - 2026 (USD Million)
  • FIG. 28 Gene therapy market, 2015 - 2026 (USD Million)
  • FIG. 29 Regional market place: Key takeaways
  • FIG. 30 Regional outlook, 2015 & 2026
  • FIG. 31 North America hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 32 U.S. hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 33 Canada hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 34 Europe hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 35 UK hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 36 Germany hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 37 France hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 38 Spain hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 39 Italy hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 40 Asia Pacific hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 41 Japan hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 42 China hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 43 India hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 44 South Korea hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 45 Thailand hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 46 Latin America hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 47 Brazil hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 48 Mexico hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 49 Argentina hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 50 Columbia hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 51 MEA hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 52 South Africa hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 53 Saudi Arabia hemophilia market, 2015 - 2026 (USD Million)
  • FIG. 54 Strategy framework
目次
Product Code: 978-1-68038-989-0

The global hemophilia market is expected to reach USD 16.9 billion by 2026, according to a new report by Grand View Research, Inc. Increasing need for diagnosis of the target population in order to initiate prophylaxis treatment and supportive government programs is expected to be the vital impact rendering driver.

CDC's National Center on Birth Defects and Developmental Disabilities (NCBDDD) undertakes initiatives to improving the public understanding of blood disorders and associated complications. For instance, NCBDDD supported the 'The Red Tie Challenge' initiated by the National Hemophilia Foundation (NHF) in order to spread awareness about blessing disorders such as Von Willebrand disease, hemophilia and other rare bleeding disorders. Such initiatives are anticipated to boost the market growth

The market players are predicted to adopt strategies such as pipeline product development and geographic expansion in underdeveloped and developing regions, such as Middle Eastern and West African countries.

As of 2015, federal bodies such as the World Federation Hemophilia have vast information and treatment regulation in about 172 countries, of which 20 were added in 2015, including Nigeria, Togo, Mali, Zambia, Mauritania, and others.

Competitive pricing strategy is a vital factor promoting market players' growth over the forecast period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower price than the existing vastly used drug Advate.

Further key findings from the report suggest:

Hemophilia B is expected to be the fastest growing hemophilia type over the forecast period, at a CAGR of 5.8%.

The other segment, owing to spurt in the number of patients diagnosed with von Willebrand Disease (VWD), is also anticipated to witness lucrative growth over the forecast period.

On-demand treatment dominated the segment over the forecast period and is expected to contribute more than 50.0% by 2026.

On the basis of therapy, gene therapy is expected to be the fastest growing segment as a result of increasing R&D and innovations in the field. Furthermore, replacement therapy is expected to witness lucrative growth due to the launch of extended half-life versions of currently available drugs.

Major market players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer, Inc., and Bayer Healthcare. Most of the companies are actively involved in the awareness and treatment programs launched by regional governments and hemophilia associations.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third-party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis, by Stage
  • 3.4. User perspective analysis
    • 3.4.1. Consumer Behavior Analysis
    • 3.4.2. Market Influencer Analysis
  • 3.5. List of Key End-users, by region / by product / by country
  • 3.6. Regulatory Framework
    • 3.6.1. Reimbursement framework
    • 3.6.2. Standards & Compliances
  • 3.7. Market Dynamics
    • 3.7.1. Market Driver Analysis
    • 3.7.2. Rising neonatal population driving diagnostic rate
    • 3.7.3. Favorable government initiatives
    • 3.7.4. Rising R & D and new product development
    • 3.7.5. Rising adoption for prophylaxis treatment
    • 3.7.6. Market Restraint Analysis
    • 3.7.7. High cost of treatment
    • 3.7.8. Industry Challenges
    • 3.7.9. Low adoption rate to advanced technologies
  • 3.8. Hemophilia: Market Analysis Tools
    • 3.8.1. Industry Analysis - Porter's
      • 3.8.1.1. Supplier Power: (Low)
      • 3.8.1.2. Buyer Power: (Moderate)
      • 3.8.1.3. Substitution Threat: (Moderate)
      • 3.8.1.4. Threat from new entrant: (Moderate)
      • 3.8.1.5. Competitive rivalry: (High)
    • 3.8.2. PESTEL Analysis
      • 3.8.2.1. Political Landscape
      • 3.8.2.2. Environmental Landscape
      • 3.8.2.3. Social Landscape
      • 3.8.2.4. Technology Landscape
      • 3.8.2.5. Legal Landscape
    • 3.8.3. Major Deals & Strategic Alliances Analysis
      • 3.8.3.1. Joint Ventures
      • 3.8.3.2. Mergers & Acquisitions
      • 3.8.3.3. Licensing & Partnership
      • 3.8.3.4. Technology Collaborations
      • 3.8.3.5. Strategic Divestments
    • 3.8.4. Market Entry Strategies

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2015 - 2026 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Type market share analysis, 2018 & 2026
  • 4.3. Segment Dashboard
  • 4.4. Global Hemophilia Market, by Type, 2015 to 2026
  • 4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 4.5.1. Hemophilia A
    • 4.5.2. Hemophilia B
    • 4.5.3. Hemophilia C
    • 4.5.4. Others

Chapter 5. Hemophilia Market: Segment Analysis, By Treatment, 2015 - 2026 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Type market share analysis, 2018 & 2026
  • 5.3. Segment Dashboard
  • 5.4. Global Hemophilia Market, by Treatment, 2015 to 2026
  • 5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 5.5.1. Replacement therapy
    • 5.5.2. ITI therapy
    • 5.5.3. Gene therapy

Chapter 6. Hemophilia Market: Segment Analysis, By Therapy, 2015 - 2026 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Type market share analysis, 2018 & 2026
  • 6.3. Segment Dashboard
  • 6.4. Global Hemophilia Market, by Therapy, 2015 to 2026
  • 6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
    • 6.5.1. On-demand
    • 6.5.2. Prophylaxis

Chapter 7. Hemophilia Market: Regional Market Analysis, 2015 - 2026 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2018 & 2026
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
  • 7.5. Regional Market Share and Leading Players, 2018
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.6.1. North America
    • 7.6.2. Europe
    • 7.6.3. Asia Pacific
    • 7.6.4. Latin America
    • 7.6.5. Middle East & Africa
  • 7.7. Market Size, & Forecasts, and Trend Analysis, 2018 to 2025:
  • 7.8. North America
    • 7.8.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.8.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.8.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.8.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.8.5. U.S.
      • 7.8.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.8.6. Canada
      • 7.8.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.9. Europe
    • 7.9.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.9.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.9.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.9.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.5. Germany
      • 7.9.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.6. UK
      • 7.9.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.7. France
      • 7.9.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.8. Italy
      • 7.9.8.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.9.9. Spain
      • 7.9.9.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.10. Asia Pacific
    • 7.10.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
      • 7.10.1.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.1.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.1.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.2. China
      • 7.10.2.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.2.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.2.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.3. Japan
      • 7.10.3.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.3.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.3.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.4. India
      • 7.10.4.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.4.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.4.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.5. Thailand
      • 7.10.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.10.6. South Korea
      • 7.10.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.11. Latin America
    • 7.11.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.11.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.11.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.11.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.5. Brazil
      • 7.11.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.6. Mexico
      • 7.11.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.7. Argentina
      • 7.11.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.11.8. Columbia
      • 7.11.8.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.11.8.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.11.8.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
  • 7.12. Middle East and Africa
    • 7.12.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
    • 7.12.2. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
    • 7.12.3. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
    • 7.12.4. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.5. South Africa
      • 7.12.5.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.5.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.5.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.6. Saudi Arabia
      • 7.12.6.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.6.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.6.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)
    • 7.12.7. UAE
      • 7.12.7.1. Market estimates and forecast, by type, 2015 - 2026 (USD Million)
      • 7.12.7.2. Market estimates and forecast, by treatment, 2015 - 2026 (USD Million)
      • 7.12.7.3. Market estimates and forecast, by therapy, 2015 - 2026 (USD Million)

Chapter 8. Hemophilia Market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2018
  • 8.4. Public Companies
    • 8.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.4.2. Company Market Share/Ranking, by region
    • 8.4.3. Competitive Dashboard Analysis
      • 8.4.3.1. Market Differentiators
      • 8.4.3.2. Synergy Analysis: Major Deals & Strategic Alliances
  • 8.5. Private Companies
    • 8.5.1. List of key emerging companies' /technology disruptors/innovators
    • 8.5.2. Funding Outlook (Optional)
    • 8.5.3. Regional network map
    • 8.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
  • 8.6. Supplier Ranking
  • 8.7. Key companies profiled
    • 8.7.1. Novo Nordisk
      • 8.7.1.1. Company Overview
      • 8.7.1.2. Financial Performance
      • 8.7.1.3. Product Benchmarking
      • 8.7.1.4. Strategic Initiatives
    • 8.7.2. Biogen.
      • 8.7.2.1. Company Overview
      • 8.7.2.2. Financial Performance
      • 8.7.2.3. Product Benchmarking
      • 8.7.2.4. Strategic Initiatives
    • 8.7.3. Chugai Pharmaceutical
      • 8.7.3.1. Company Overview
      • 8.7.3.2. Financial Performance
      • 8.7.3.3. Product Benchmarking
      • 8.7.3.4. Strategic Initiatives
    • 8.7.4. Bayer Healthcare
      • 8.7.4.1. Company Overview
      • 8.7.4.2. Financial Performance
      • 8.7.4.3. Product Benchmarking
      • 8.7.4.4. Strategic Initiatives
    • 8.7.5. Pfizer.
      • 8.7.5.1. Company Overview
      • 8.7.5.2. Financial Performance
      • 8.7.5.3. Product Benchmarking
      • 8.7.5.4. Strategic Initiatives
    • 8.7.6. Shire Plc
      • 8.7.6.1. Company Overview
      • 8.7.6.2. Financial Performance
      • 8.7.6.3. Product Benchmarking
      • 8.7.6.4. Strategic Initiatives
    • 8.7.7. Baxalta (Baxter Healthcare)
      • 8.7.7.1. Company Overview
      • 8.7.7.2. Financial Performance
      • 8.7.7.3. Product Benchmarking
      • 8.7.7.4. Strategic Initiatives
    • 8.7.8. CSL Behring.
      • 8.7.8.1. Company Overview
      • 8.7.8.2. Financial Performance
      • 8.7.8.3. Product Benchmarking
      • 8.7.8.4. Strategic Initiatives
    • 8.7.9. Octapharma.
      • 8.7.9.1. Company Overview
      • 8.7.9.2. Financial Performance
      • 8.7.9.3. Product Benchmarking
      • 8.7.9.4. Strategic Initiatives

Chapter 9. KOL Commentary

Chapter 10. Recommendations

Back to Top